Pneumonia Vaccines Market Demand and Competitive Analysis by Leading Manufacturers 2022-2030

The Global Pneumonia Vaccines Market size is estimated to be USD 7.76 billion in 2019 and is predicted to reach USD 12.86 billion by 2030 with a CAGR of 4.7% from 2020-2030.

Pneumonia is a disease which led to contamination of lungs by the microorganisms such as bacteria, virus, fungi and others which grows around the alveoli and obstructs the oxygen exchange which can lead to lack of oxygen in the body. It can be prevented by the means of vaccination. Pneumonia can affect any individual including infants to the geriatric population which can also led to the development of pus in alveoli which can cause breathing issues, infants and elderly people are more prone to such infections.

Access Full Description of this report at:-

https://www.nextmsc.com/report/pneumonia-vaccines-market

Competitive Landscape

The pneumonia vaccines market, which is highly competitive, consists of various market players. Some of the major market players include LG Chem Ltd., Glaxosmithkline plc., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., SK Bioscience, Pnuvax Incorporated, Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited), Walvax Biotechnology Co., Ltd. and Serum Institute of India Pvt. Ltd., among others.

Over the period of time there have been various developments taken place in the market and also expected to takes place in near future. For instance, in April 2019, Pfizer Inc. has announced the presentation of data from a Phase 2 study of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes contained in the vaccine in adults aged 18 years and older. The presentation was delivered at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands. Pfizer’s 20vPnC candidate includes the 13 serotypes contained in Prevnar 13 plus seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F).

Market Dynamics and Trends

The developing and modernizing healthcare facilities and infrastructure in the developing economies over the forecast period are expected to enhance the market growth. Moreover, technological advancement coupled with increased prevalence of pneumonia are further expected to fuel the growth of pneumonia vaccine market.

The other factors include increased public awareness about vaccination and increase in government initiatives and non-government initiatives to promote vaccination are also expected to further accelerate the market growth. However, high cost of pneumonia vaccines and high cost of the development of vaccines are expected to adversely affect the growth of pneumonia vaccines market. Moreover, increased inclination towards protein based vaccines are further expected to create ample opportunities in the pneumonia vaccines market in the near future.

Request sample copy of this report at:-

https://www.nextmsc.com/pneumonia-vaccines-market/request-sample

Market Segmentations and Scope of the Study:

The global pneumonia vaccines market share is analyzed on the basis of vaccine type, product type, sector, distribution channel and geography. On the basis of product type, the market is segmented into Prevnar 13, Synflorix, and Pneumovax 23. On the basis of vaccine type, the market is divided into Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine. Based on sector, he market is fragmented into public and private. Based on distribution channel, the market is divided into Distribution Partner Companies, Non-governmental Organizations (NGO), and Government Authorities. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis

North America is expected to account for the major market share owing to the increased adoption of pneumonia vaccines over the forecast period. Moreover, presence of advanced healthcare infrastructure and technological advancement are further expected to promote the growth of pneumonia vaccines market over the forecast period.

Asia Pacific is expected to grow rapidly with increasing market share owing to the increased prevalence of pneumonia and increased public awareness about vaccination. Furthermore, increase in government initiatives and non-government initiatives to further increase the vaccination is further expected propel the growth of pneumonia vaccine market.

Contact:
Phone Number: +1-217-650-7991
E-mail: info@nextmsc.com

About Next Move Strategy Consulting:

Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more insights, please visit, https://www.nextmsc.com

This release was published on openPR.